Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_1

Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)

NCT00116376

completedphase_1

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

NCT00107237

completedphase_1

Study of Oral AEE788 in Adults With Advanced Cancer

NCT00118456

Clinical Trials (3)

Showing 3 of 3 trials

NCT00116376Phase 1

Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)

Completed

NCT00107237Phase 1

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

Completed

NCT00118456Phase 1

Study of Oral AEE788 in Adults With Advanced Cancer

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3